Homogeneously high expression of CD32b makes it a potential target for CAR-T therapy for chronic lymphocytic leukemia

CD19 chimeric antigen receptor (CAR)-T cells have been used to treat patients with refractory chronic lymphocytic leukemia (CLL). However, approximately 50% of patients do not respond to this therapy. To improve the clinical outcome of these patients, it is necessary to develop strategies with other...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Guoling, Sun, Xiaolei, Zuo, Shiyu, Li, Chuo, Niu, Qing, Xia, Yonghui, Meng, Yuan, Liu, Min, Fang, Zihao, Yang, Xi, Jiang, Yanyu, Wang, Sheng, Cui, Haidong, Huang, Huifang, Jiang, Erlie, Zhou, Dongming, Deng, Qi, Pan, Jing, Feng, Xiaoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447616/
https://www.ncbi.nlm.nih.gov/pubmed/34530888
http://dx.doi.org/10.1186/s13045-021-01160-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447616/
https://www.ncbi.nlm.nih.gov/pubmed/34530888
http://dx.doi.org/10.1186/s13045-021-01160-9

Ejemplares similares